CMAX — CareMax, Inc.

CareMax Q4 2023 Earnings Call Summary

1. Key Financial Results and Metrics

• Membership: CareMax ended 2023 with 111,500 Medicare Advantage members, meeting its membership targets.
• Revenue: Reported revenue for 2023 was $751 million, slightly below guidance due to headwinds from prior-year developments (PYD) and reserves.
• Adjusted EBITDA: For 2023, adjusted EBITDA was negative $63 million, impacted by $42 million in PYD and $15 million in reserves for adverse deviation.
• Medical Expense Ratio (MER): The total MER for 2023 was 91.5%, affected by PYD, increased benefit card expenses, and Medicaid redeterminations.
• Cash Position: Ended the year with approximately $66 million in cash after drawing $60 million from delayed-draw term loans.

2. Strategic Updates and Business Highlights

• Cost-Saving Initiatives: Implemented measures expected to yield $20 million in annualized cash savings, including workforce streamlining and center consolidations in South Florida, which have already realized $5 million in savings.
• Quality Ratings: Achieved a 5-star quality rating across all CareMax centers for the third consecutive year.
• Operational Review: Conducted a comprehensive operational review leading to structural changes aimed at optimizing performance and profitability rather than growth.
• De Novo Centers: Established a critical mass in underserved communities, with plans to monetize these assets through strategic discussions with potential partners.

3. Forward Guidance and Outlook

• 2024 Expectations: Anticipated to be a transition year with a focus on balancing reimbursements and expenditures. Management is optimistic about improving medical expense growth rates and star ratings, which could positively impact revenues in 2025.
• Risk Management: Plans to take on increased risk in Medicare Advantage contracts, with 35% of the MSO MA population now under full risk, up from 15% in 2023.

4. Bad News, Challenges, or Points of Concern

• Financial Headwinds: The company faced challenges from increased medical and flex card utilization, which significantly impacted financial results. Flex card expenses nearly tripled from the previous year, contributing over $30 million to medical expenses.
• Goodwill Impairment: Reported a non-cash goodwill impairment of $369 million in Q4, affecting GAAP net income.
• Data Management Issues: Encountered difficulties with the timeliness and accuracy of data from new health plan contracts, which contributed to prior-year developments and increased medical expenses.
• Uncertainty in 2024 Guidance: Management refrained from providing precise guidance for 2024 due to ongoing structural changes and the uncertain economic environment.

5. Notable Q&A Insights

• Focus on Payer Relationships: Management emphasized the importance of strong relationships with legacy and new health plan partners, indicating that successful outcomes depend on shared investments and data access.
• Strategic Asset Discussions: Ongoing discussions to maximize asset value may provide liquidity and support the company through the anticipated MSSP payment later in 2024.
• Operational Adjustments: Management reiterated their commitment to optimizing operations and adjusting strategies to enhance long-term value amidst current industry challenges.

In summary, CareMax is navigating a challenging environment with strategic initiatives aimed at cost reduction and operational efficiency while preparing for a transitional year in 2024. The focus remains on improving financial stability and positioning for future growth.